Pergamon Offshore Advisors’s ResMed RMD Stock Holding History

Pergamon Offshore Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-11,180	Closed	-$630K	–	195
2015 Q2	$630K	Sell	11,180 -2,013	-15%	-$127K	0.67%	48
2015 Q1	$947K	Sell	13,193 -5,052	-28%	-$328K	0.92%	32
2014 Q4	$1.02M	Buy	+18,245	New	+$953K	0.96%	26

Other funds holding RMD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pergamon Offshore Advisors's RMD Position: Q3 2015 in Review

Pergamon Offshore Advisors sold out of ResMed (RMD) in Q3 2015, closing a stake of 11,180 shares — an estimated $630K sold.

Pergamon Offshore Advisors first reported a position in RMD in Q4 2014 and held it in 3 quarters. The position peaked at $1.02M in Q4 2014. 314 funds tracked by Wall St. Rank hold RMD as of Q3 2015.

Pergamon Offshore Advisors reported no remaining ResMed position as of Q3 2015 after selling out during the quarter.
Pergamon Offshore Advisors sold 11,180 ResMed shares in Q3 2015, an estimated $630K.
Pergamon Offshore Advisors first reported a position in ResMed in Q4 2014 and held it in 3 quarters.
Pergamon Offshore Advisors's ResMed position peaked at $1.02M in Q4 2014.
314 funds tracked by Wall St. Rank held ResMed as of Q3 2015.

Based on Pergamon Offshore Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.